tuneTypical Dose
Use a DNJ-standardized mulberry leaf extract with carbohydrate-containing meals rather than assuming a universal all-purpose dose
Botanical
Mulberry Leaf
Morus alba
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Postprandial effects can appear with the first studied meals. Longer-term glycemic effects take weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Mulberry leaf extract can blunt postprandial glucose excursions and may modestly support glycemic control, but the evidence is formulation specific and not a substitute for diabetes care.
Mulberry leaf is one of the more credible botanical options for meal-time glucose control because its human evidence repeatedly points toward reduced postprandial glucose exposure. The main active framing is usually DNJ-rich extract taken with carbohydrate-containing meals. Longer-term diabetes data exist, but they are smaller and less consistent than the meal-challenge evidence. That makes mulberry leaf a cautious adjunct for postprandial glycemic control, not a stand-alone diabetes treatment.
Mulberry leaf is usually framed around 1-deoxynojirimycin and related compounds that inhibit carbohydrate digestion and blunt postprandial glucose absorption. The clinically useful human evidence fits that meal-time glucose-control mechanism better than broad weight-loss or diabetes-reversal claims.
Article
Mulberry Leaf
Mulberry leaf is one of the better examples of a supplement where the strongest claim is narrower than the marketing.
The main evidence-supported use is blunting postprandial glucose excursions, especially when a DNJ-containing mulberry leaf extract is taken with a carbohydrate-containing meal. A 2023 systematic review and meta-analysis found improvements in glycemic traits overall, but the most practical and consistent signal was around postprandial glucose handling rather than dramatic disease reversal.1
Where it seems most useful
The strongest use case is:
- meal-time reduction of postprandial glucose rise
The weaker but plausible use case is:
- adjunctive glycemic support in type 2 diabetes
A 2023 randomized crossover trial in adults with type 2 diabetes found that a meal-time blend containing mulberry leaf extract lowered postprandial glucose and insulin exposure over 3 hours.2 That supports the meal-time framing, but the tested product was a blend, so it is not proof that every mulberry product works the same way.
A 2017 pilot trial in type 2 diabetes also suggested a favorable adjunctive signal, but it was small and should stay secondary to the larger pooled literature.3
Dosing
The evidence is very formulation specific. Mulberry leaf products are often standardized to 1-deoxynojirimycin, and the most defensible use is with meals rather than as a generic anytime glucose-support capsule.
Safety
Mulberry leaf extract appears reasonably well tolerated in the small human literature. The main practical risk is additive glucose lowering in people already using antidiabetic medications, especially if they are testing it aggressively around meals.
Bottom line
Mulberry leaf is a reasonable adjunct for reducing postprandial glucose excursions when the product is standardized and used with meals. That is a legitimate but still limited use case. It should not be treated like a stand-alone diabetes therapy or broad metabolic cure-all.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced postprandial glucose excursions
Secondary Outcomes
- Possible modest adjunctive improvement in longer-term glycemic control
- Evidence depends heavily on extract standardization and with-meal use
Safety
Contraindications and Interactions
Contraindications
- Recurrent hypoglycemia risk
Side effects
- Mild GI discomfort
Interactions
- Antidiabetic medications
Avoid if
- You are using it instead of diabetes treatment
- You cannot verify DNJ standardization or formulation quality
Evidence
Study-level References
ml-SRC-001Systematic review and meta-analysis
Sourceopen_in_newNguyen TTH, Park C, Kwon O. Effect of mulberry leaf or mulberry leaf extract on glycemic traits: a systematic review and meta-analysis. Sci Rep. 2023;13(1):748. doi:10.1038/s41598-023-27852-7. PMID:36644880.
Population: Adults from randomized and nonrandomized clinical trials evaluating mulberry leaf or mulberry leaf extract on glycemic traits.
Dose protocol: Various mulberry leaf and mulberry leaf extract protocols
Key findings: Improved glycemic traits overall, with the clearest practical signal for postprandial glucose control.
Notes: Best current overview for the supplement’s main framing.
Paper content
This is the best current overview for mulberry leaf. The pooled evidence supports improved glycemic traits, but the literature is heterogeneous and often built around short-term meal-challenge studies or small adjunctive diabetes trials. The practical signal is strongest for blunting postprandial glucose excursions rather than for broad stand-alone diabetes treatment claims.
ml-SRC-002Randomized crossover trial
Sourceopen_in_newMarum AP, Brownlee IA, Brouns F, et al. A randomized, placebo-controlled crossover study to evaluate postprandial glucometabolic effects of mulberry leaf extract, vitamin D, chromium, and fiber in people with type 2 diabetes. Sci Rep. 2023;13(1):3300. doi:10.1038/s41598-023-29651-6. PMID:36855010.
Population: Adults with type 2 diabetes.
Dose protocol: 250 mg mulberry leaf extract within a 2 g meal-time blend
Key findings: Reduced postprandial glucose and insulin exposure in adults with type 2 diabetes.
Notes: Useful modern meal-time trial, but formulation specific.
Paper content
This trial reinforces the practical meal-time use case for mulberry leaf extract. It supports postprandial glucose blunting in people with type 2 diabetes, but the formulation was a blend rather than isolated mulberry leaf extract, so the findings should not be overgeneralized.
ml-SRC-003Double-blind randomized placebo-controlled crossover trial
Sourceopen_in_newThondre PS et al. Understanding the Impact of Different Doses of Reducose Mulberry Leaf Extract on Blood Glucose and Insulin Responses after Eating a Complex Meal: Results from a Double-Blind, Randomised, Crossover Trial. Nutrients. 2024;16(11):1670. doi:10.3390/nu16111670. PMID:38892603.
Population: Healthy adults completing a crossover meal-challenge trial
Dose protocol: 200 mg to 250 mg standardized mulberry leaf extract before a mixed meal
Key findings: All tested doses lowered postprandial glucose and insulin exposure versus placebo in a crossover meal trial.
Notes: High-value modern trial because it isolates a standardized mulberry extract and shows a repeatable premeal effect.
Paper content
In a double-blind crossover trial, 200 mg to 250 mg of a standardized mulberry leaf extract taken before a mixed meal lowered both postprandial glucose and insulin exposure in healthy adults. The signal was consistent across all tested doses, which strengthens the case for meal-time glucose-control framing.
ml-SRC-004Randomized controlled pilot trial
Sourceopen_in_newMudra M, Ercan-Fang N, Zhong L, Furne J, Levitt M. Impact of mulberry leaf extract on type 2 diabetes (Mul-DM): A randomized, placebo-controlled pilot study. Complement Ther Med. 2017;32:105-108. doi:10.1016/j.ctim.2017.05.008. PMID:28619294.
Population: Adults with type 2 diabetes.
Dose protocol: Trial-specific mulberry leaf extract protocol over about 3 months
Key findings: Small pilot signal for adjunctive benefit in type 2 diabetes.
Notes: Supportive secondary anchor, not a decisive stand-alone trial.
Paper content
This pilot trial is small, but it supports the idea that mulberry leaf extract may have adjunctive value in type 2 diabetes. The main limitation is scale. It is not strong enough to stand alone, but it helps justify cautious diabetes-adjunct framing when combined with the meal-time and meta-analytic literature.
ml-SRC-005Randomized crossover trial with in vitro component.
Sourceopen_in_newSun Y, Niu X, Wang Y, et al. Effects of mulberry leaf and corn silk extracts against alpha-amylase and alpha-glucosidase in vitro and on postprandial glucose in prediabetic individuals: a randomized crossover trial. Nutrients. 2025;17(21):3438. doi:10.3390/nu17213438. PMID:41228506.
Population: Adults with prediabetes.
Dose protocol: Mulberry leaf and corn silk extracts in modified milk products, randomized crossover in prediabetic adults
Key findings: In overweight prediabetic subgroup, reduced 1-hour glucose (-0.84 mmol/L), max glucose (-0.54 mmol/L), and glucose excursion (-0.62 mmol/L) vs pure milk. Full cohort not significant.
Notes: Combination product limits attribution to mulberry alone. Small sample (n=11). Supports meal-time glucose-blunting mechanism.
Paper content
This randomized crossover trial tested mulberry leaf and corn silk extracts combined with modified milk products in 11 prediabetic adults. In vitro, both extracts inhibited alpha-amylase and alpha-glucosidase dose-dependently with synergistic effects. Overall in the full cohort, no significant postprandial glucose differences emerged between interventions. However, in the overweight subgroup, GOS milk with mulberry leaf and corn silk extracts significantly reduced 1-hour glucose (-0.84 mmol/L), maximum glucose (-0.54 mmol/L), and glucose excursion (-0.62 mmol/L) versus pure milk. The study supports the meal-time glucose-blunting framing of mulberry leaf but is limited by its small size, combination product design, and subgroup-dependent findings. The in vitro enzyme inhibition data support the mechanistic basis of the effect.